{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:04:50Z","timestamp":1776067490871,"version":"3.50.1"},"reference-count":198,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Multiple sclerosis (MS) reflects a dynamic interplay between peripheral immune activation and compartmentalized inflammation within the central nervous system (CNS). While current disease-modifying therapies effectively reduce relapse activity driven by transient peripheral immune infiltration, their impact on progressive disability remains limited, prompting interest in strategies targeting CNS-resident immune mechanisms. Bruton\u2019s tyrosine kinase (BTK), expressed in B cells and myeloid-derived cells, including microglia, serves as a shared intracellular signaling node linking adaptive and innate immune pathways. Second-generation BTK inhibitors, including evobrutinib, tolebrutinib, fenebrutinib, remibrutinib, and orelabrutinib, have advanced through Phase II-III development in MS. These agents differ in binding mode, selectivity, pharmacokinetics, CNS penetration, and safety profiles, distinctions that may influence stage-specific therapeutic performance. Recent trials across relapsing and progressive phenotypes have yielded heterogeneous outcomes. Divergent signals in primary and secondary progressive MS reflect underlying biological heterogeneity and suggest that therapeutic responsiveness may depend on residual inflammatory activity, lesion biology, and pharmacologic characteristics. Emerging biomarker frameworks further emphasize the importance of stratifying inflammatory activity and degenerative progression when interpreting trial data. This review integrates molecular pharmacology and the most recent clinical evidence available through 2026 to examine how pharmacologic properties translate into stage-dependent therapeutic positioning. We also consider safety constraints within a disease-stage-specific benefit-risk framework, aiming to clarify the evolving role of BTK inhibition in MS.<\/jats:p>","DOI":"10.3390\/molecules31081272","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:29:29Z","timestamp":1776065369000},"page":"1272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bruton\u2019s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1817-4039","authenticated-orcid":false,"given":"Qiying","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-6813","authenticated-orcid":false,"given":"Siming","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medicine, MetroHealth Medical Center, Cleveland, OH 44109, USA"},{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","article-title":"Multiple sclerosis: Molecular pathogenesis and therapeutic intervention","volume":"10","author":"Eixarch","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41583-024-00823-z","article-title":"The neuropathobiology of multiple sclerosis","volume":"25","author":"Woo","year":"2024","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: The 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: Time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/WCO.0000000000001262","article-title":"Understanding multiple sclerosis as a disease spectrum: Above and below the clinical threshold","volume":"37","author":"Krieger","year":"2024","journal-title":"Curr. Opin. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1474-4422(25)00436-3","article-title":"Multiple sclerosis research in 2025: Earlier diagnosis and halting progression","volume":"25","author":"Pittock","year":"2026","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104789","DOI":"10.1016\/j.ebiom.2023.104789","article-title":"Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis","volume":"96","author":"Touil","year":"2023","journal-title":"EBioMedicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s40478-025-02122-9","article-title":"Demyelinated lesion associated compartmental inflammation in progressive multiple sclerosis brains","volume":"13","author":"Najm","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: From pathophysiology to therapeutic strategies","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","article-title":"Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis","volume":"18","author":"Yong","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102921","DOI":"10.1016\/j.arr.2025.102921","article-title":"From pathogenesis to precision medicine: Targeting immune imbalance in multiple sclerosis","volume":"113","author":"Pithakumar","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The Immune Response in Multiple Sclerosis","volume":"17","author":"Farez","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: Safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaneurol.2022.1929","article-title":"Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis","volume":"79","author":"Portaccio","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00601","DOI":"10.1016\/j.neurot.2025.e00601","article-title":"Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies","volume":"22","author":"Rizvi","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100960","DOI":"10.1016\/j.medj.2025.100960","article-title":"Progressive multiple sclerosis: Six trials to watch","volume":"7","author":"Rocca","year":"2026","journal-title":"Med"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"de Seze, J., Maillart, E., Gueguen, A., Laplaud, D.A., Michel, L., Thouvenot, E., Zephir, H., Zimmer, L., Biotti, D., and Liblau, R. (2023). Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1004795"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Macaron, G., and Ontaneda, D. (2019). Diagnosis and Management of Progressive Multiple Sclerosis. Biomedicines, 7.","DOI":"10.3390\/biomedicines7030056"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s43440-024-00642-0","article-title":"Multiple sclerosis: A narrative overview of current pharmacotherapies and emerging treatment prospects","volume":"76","author":"Olejnik","year":"2024","journal-title":"Pharmacol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102012","DOI":"10.1016\/j.disamonth.2025.102012","article-title":"Multiple sclerosis updates and the safety and efficacy of Bruton tyrosine kinase inhibitors in it: A systematic review","volume":"71","author":"Prajjwal","year":"2025","journal-title":"Disease-a-Month"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton\u2019s tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Elkjaer, M.L., Waede, M.R., Kingo, C., Damsbo, K., and Illes, Z. (2023). Expression of Bruton s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1264128"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton\u2019s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Garg, N., Padron, E.J., Rammohan, K.W., and Goodman, C.F. (2022). Bruton\u2019s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11206139"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Dammeijer","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1474-4422(25)00238-8","article-title":"Bruton\u2019s tyrosine kinase inhibitors for multiple sclerosis","volume":"24","author":"Airas","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11910-022-01229-z","article-title":"Bruton\u2019s Tyrosine Kinase Inhibition in Multiple Sclerosis","volume":"22","author":"Schneider","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kramer","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17562864241233041","DOI":"10.1177\/17562864241233041","article-title":"A review of Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis","volume":"17","author":"Airas","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fares, A., Carracedo Uribe, C., Martinez, D., Rehman, T., Silva Rondon, C., and Sandoval-Sus, J. (2024). Bruton\u2019s Tyrosine Kinase Inhibitors: Recent Updates. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042208"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton\u2019s tyrosine kinase (Btk): Function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1359-6101(99)00019-2","article-title":"Tec family of protein-tyrosine kinases: An overview of their structure and function","volume":"10","author":"Mano","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1074-7613(00)80189-2","article-title":"Tec kinases: A family with multiple roles in immunity","volume":"12","author":"Yang","year":"2000","journal-title":"Immunity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e06074","DOI":"10.7554\/eLife.06074","article-title":"Autoinhibition of Bruton\u2019s tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate","volume":"4","author":"Wang","year":"2015","journal-title":"Elife"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9390","DOI":"10.1073\/pnas.1819301116","article-title":"Structural mechanism for Bruton\u2019s tyrosine kinase activation at the cell membrane","volume":"116","author":"Wang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zain, R., and Vihinen, M. (2021). Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.694853"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Najmi, A., Thangavel, N., Mohanan, A.T., Qadri, M., Albratty, M., Ashraf, S.E., Saleh, S.F., Nayeem, M., and Mohan, S. (2023). Structural Complementarity of Bruton\u2019s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030400"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15604","DOI":"10.1038\/s41598-017-10697-0","article-title":"Millisecond dynamics of BTK reveal kinome-wide conformational plasticity within the apo kinase domain","volume":"7","author":"Sultan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"18671","DOI":"10.1038\/s41598-021-98255-7","article-title":"Target modulation and pharmacokinetics\/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection","volume":"11","author":"Byun","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1021\/acsptsci.4c00540","article-title":"Comprehensive Characterization of Bruton\u2019s Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures","volume":"8","author":"Darragh","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1074-7613(00)80591-9","article-title":"BLNK: A central linker protein in B cell activation","volume":"9","author":"Fu","year":"1998","journal-title":"Immunity"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1097-2765(02)00739-6","article-title":"Amplification of B cell antigen receptor signaling by a Syk\/ITAM positive feedback loop","volume":"10","author":"Rolli","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1074-7613(00)00079-0","article-title":"BCAP: The tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation","volume":"13","author":"Okada","year":"2000","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"16201","DOI":"10.1074\/jbc.M100873200","article-title":"Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk","volume":"276","author":"Saito","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.it.2004.02.011","article-title":"The pre-BCR checkpoint as a cell-autonomous proliferation switch","volume":"25","author":"Hendriks","year":"2004","journal-title":"Trends Immunol."},{"key":"ref_52","first-page":"67","article-title":"BTK Signaling in B Cell Differentiation and Autoimmunity","volume":"393","author":"Corneth","year":"2016","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis\u2014From targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41577-021-00652-6","article-title":"B cells in central nervous system disease: Diversity, locations and pathophysiology","volume":"22","author":"Jain","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1038\/s41467-024-54430-8","article-title":"BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis","volume":"15","author":"Gruber","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ben Mkaddem, S., Benhamou, M., and Monteiro, R.C. (2019). Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00811"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-065X.1999.tb01372.x","article-title":"Fc receptor signaling and trafficking: A connection for antigen processing","volume":"172","author":"Amigorena","year":"1999","journal-title":"Immunol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"26258","DOI":"10.1074\/jbc.M301484200","article-title":"Bruton\u2019s tyrosine kinase is a Toll\/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4","volume":"278","author":"Jefferies","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kawasaki, T., and Kawai, T. (2014). Toll-like receptor signaling pathways. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00461"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"14488","DOI":"10.1038\/srep14488","article-title":"Chronic TLR Stimulation Controls NLRP3 Inflammasome Activation through IL-10 Mediated Regulation of NLRP3 Expression and Caspase-8 Activation","volume":"5","author":"Gurung","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41582-022-00624-x","article-title":"The role of glial cells in multiple sclerosis disease progression","volume":"18","author":"Healy","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/brain\/awaa158","article-title":"Molecular signature of slowly expanding lesions in progressive multiple sclerosis","volume":"143","author":"Jackle","year":"2020","journal-title":"Brain"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11864-025-01339-z","article-title":"Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment","volume":"26","author":"Shah","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","article-title":"Comparative CNS Pharmacology of the Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis","volume":"24","author":"Turner","year":"2024","journal-title":"Drugs R. D"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"177747","DOI":"10.1016\/j.ejphar.2025.177747","article-title":"Next generation Bruton\u2019s tyrosine kinase inhibitors\u2014Characterization of in vitro potency and selectivity","volume":"1002","author":"Pulz","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e200510","DOI":"10.1212\/NXI.0000000000200510","article-title":"Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B Cells","volume":"13","author":"Dybowski","year":"2026","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00401-024-02730-0","article-title":"BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair","volume":"147","author":"Geladaris","year":"2024","journal-title":"Acta Neuropathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12974-023-02877-9","article-title":"Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis","volume":"20","author":"Ferrero","year":"2023","journal-title":"J. Neuroinflamm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: Past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: Drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia","volume":"21","author":"McGinn","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: A 5-year experience","volume":"131","author":"Furman","year":"2018","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Duminuco, A., De Luca, P., Stanzione, G., Caruso, L.A., Lavenia, G., Scarso, S., Garibaldi, B., Palumbo, F.E., Vetro, C., and Palumbo, G.A. (2026). BTK Inhibition in Hematology: From CLL\/SLL to Emerging Applications Across B-Cell and Immune Disorders. Biomolecules, 16.","DOI":"10.3390\/biom16010123"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Estupinan, H.Y., Berglof, A., Zain, R., and Smith, C.I.E. (2021). Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.630942"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mouhssine, S., Maher, N., Matti, B.F., Alwan, A.F., and Gaidano, G. (2024). Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063234"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1097\/HS9.0000000000000564","article-title":"Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia","volume":"5","author":"Mulder","year":"2021","journal-title":"Hemasphere"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: A systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"104597","DOI":"10.1016\/j.critrevonc.2024.104597","article-title":"Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis","volume":"206","author":"Jaradat","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ke, L., Li, S., Huang, D., and Wang, Y. (2024). Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: A systematic review and meta-analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1413985"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","article-title":"Bruton\u2019s tyrosine kinase inhibitors: First and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)","volume":"27","author":"Thompson","year":"2018","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12272-025-01546-0","article-title":"BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies","volume":"48","author":"Kim","year":"2025","journal-title":"Arch. Pharmacal Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10637-025-01513-y","article-title":"From development to clinical success: The journey of established and next-generation BTK inhibitors","volume":"43","author":"Gupta","year":"2025","journal-title":"Investig. New Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-022-01386-1","article-title":"Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia","volume":"15","author":"Muhowski","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Robak, T., Iskierka-Jazdzewska, E., Pula, A., Robak, P., and Pula, B. (2025). The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs. J. Clin. Med., 14.","DOI":"10.3390\/jcm14228247"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Schaefer, D., and Cheng, X. (2023). Recent Advances in Covalent Drug Discovery. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050663"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cts.12713","article-title":"Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers","volume":"13","author":"Becker","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: Balancing the benefits and risks","volume":"55","author":"Barf","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Yang, Z., Wang, W., Wang, X., and Qin, Z. (2021). Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.741451"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/14740338.2014.904283","article-title":"Targeting the epidermal growth factor receptor in solid tumors: Focus on safety","volume":"13","author":"Lucchini","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton\u2019s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-22-0642","article-title":"Bruton\u2019s Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"116163","DOI":"10.1016\/j.bmc.2021.116163","article-title":"Discovery of potent and selective reversible Bruton\u2019s tyrosine kinase inhibitors","volume":"40","author":"Qiu","year":"2021","journal-title":"Bioorganic Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/cts.13162","article-title":"Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)","volume":"15","author":"Owens","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e208058","DOI":"10.1212\/WNL.0000000000208058","article-title":"Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial","volume":"102","author":"Arnold","year":"2024","journal-title":"Neurology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/13524585241234783","article-title":"Efficacy and safety results after >3.5 years of treatment with the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study","volume":"30","author":"Montalban","year":"2024","journal-title":"Mult. Scler."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): Two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1212\/WN9.0000000000000028","article-title":"Tolebrutinib Phase 2b Long-Term Extension Study: Two-Year Safety, MRI, and Clinical Efficacy Outcomes in Patients With Relapsing Multiple Sclerosis Patients","volume":"1","author":"Oh","year":"2025","journal-title":"Neurol. Open Access"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_114","unstructured":"Reich, D.S., Bar-Or, A., Vermersch, P., Oreja-Guevara, C., Traboulsee, A., Giovannoni, G., Syed, S., Sun, F., Salloum, N., and Turner, T.J. (2026, January 2). Efficacy and Safety of Tolebrutinib Versus Placebo in Primary Progressive Multiple Sclerosis: Results From the Phase 3 PERSEUS Trial. Proceedings of the ACTRIMS Forum 2026, San Diego, CA, USA."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cpt.1056","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton\u2019s Tyrosine Kinase Inhibitor","volume":"103","author":"Herman","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): A multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Dufek","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_117","unstructured":"Bar-Or, A., Oh, J., Giovannoni, G., Sormani, M., Weber, M.S., Stoll, S., Nicholas, J., von B\u00fcdingen, H., Lopez, J., and Roberts, L. (2026, January 2). Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study. Proceedings of the ACTRIMS 2026, San Diego, CA, USA."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Roche Holding AG (2025, September 11). Roche\u2019s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in both Relapsing and Primary Progressive Multiple Sclerosis. Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2025-11-10.","DOI":"10.4000\/145n5"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/acs.jmedchem.1c00926","article-title":"Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis","volume":"65","author":"Hopkins","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1002\/cti2.1295","article-title":"Next-generation Bruton\u2019s tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells","volume":"10","author":"Bame","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1021\/acs.jmedchem.4c00220","article-title":"Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis","volume":"67","author":"Himmelbauer","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1212\/WNL.98.18_supplement.2562","article-title":"Phase 3 REMODEL I\/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (P7-4.003)","volume":"98","author":"Wiendl","year":"2022","journal-title":"Neurology"},{"key":"ref_123","unstructured":"Xu, Y., Chen, X., and Tang, W. (March, January 27). Positive Phase 2 Results of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis. Proceedings of the ACTRIMS Forum 2025, West Palm Beach, FL, USA."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e00602","DOI":"10.1016\/j.neurot.2025.e00602","article-title":"Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment","volume":"22","author":"Naydovich","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1212\/01.wnl.0000187122.71735.1f","article-title":"Predictors of relapse rate in MS clinical trials","volume":"65","author":"Held","year":"2005","journal-title":"Neurology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/1352458511406309","article-title":"Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design","volume":"17","author":"Nicholas","year":"2011","journal-title":"Mult. Scler."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"a028969","DOI":"10.1101\/cshperspect.a028969","article-title":"Magnetic Resonance Imaging in Multiple Sclerosis","volume":"8","author":"Hemond","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1756286419826547","DOI":"10.1177\/1756286419826547","article-title":"Evolution of clinical trials in multiple sclerosis","volume":"12","author":"Zhang","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756285614546855","article-title":"Teriflunomide in the treatment of multiple sclerosis: Current evidence and future prospects","volume":"7","author":"Oh","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"Wolinsky","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Pachner","year":"2014","journal-title":"Drugs"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"key":"ref_135","unstructured":"(2026, April 03). Media Update: Patient Enrollment of Phase III Tolebrutinib Trials Paused in the U.S. Available online: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-06-30-05-30-00-2471767."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jns.2009.07.017","article-title":"Statistical methods for the analysis of relapse data in MS clinical trials","volume":"285","author":"Wang","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1177\/1352458513481009","article-title":"Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression","volume":"19","author":"Steinvorth","year":"2013","journal-title":"Mult. Scler."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"101947","DOI":"10.1016\/j.smim.2025.101947","article-title":"The role of the adaptive immune system in the initiation and persistence of multiple sclerosis","volume":"78","author":"Afzali","year":"2025","journal-title":"Semin. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: Pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","article-title":"Primary-progressive multiple sclerosis","volume":"6","author":"Miller","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary Progressive Multiple Sclerosis: New Insights","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: Interactions, checks, and balances","volume":"20","author":"Li","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_144","first-page":"527","article-title":"Progressive multiple sclerosis: From pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1093\/brain\/aws189","article-title":"Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis","volume":"135","author":"Choi","year":"2012","journal-title":"Brain"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Sempik, I., Dziadkowiak, E., Moreira, H., Zimny, A., and Pokryszko-Dragan, A. (2024). Primary Progressive Multiple Sclerosis\u2014A Key to Understanding and Managing Disease Progression. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168751"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/brain\/117.4.759","article-title":"A comparison of the pathology of primary and secondary progressive multiple sclerosis","volume":"117","author":"Revesz","year":"1994","journal-title":"Brain"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00401-012-0953-0","article-title":"Primary progressive multiple sclerosis: Part of the MS disease spectrum or separate disease entity?","volume":"123","author":"Antel","year":"2012","journal-title":"Acta Neuropathol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e200279","DOI":"10.1212\/NXI.0000000000200279","article-title":"Neurofilament Light Chain Serum Levels Mirror Age and Disability in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Study","volume":"11","author":"Husseini","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","article-title":"Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis","volume":"81","author":"Cross","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e2147588","DOI":"10.1001\/jamanetworkopen.2021.47588","article-title":"Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation","volume":"5","author":"Gafson","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","article-title":"Serum neurofilament light as a biomarker in progressive multiple sclerosis","volume":"95","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e200427","DOI":"10.1212\/NXI.0000000000200427","article-title":"Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management","volume":"12","author":"Nicholas","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/acn3.52187","article-title":"Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis","volume":"11","author":"Madill","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J. Neurol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Enache, I.I., Tiu, V.E., Anghel, C.A., Tiu, C., Popa-Cherecheanu, A., Bostan, M., Scippa, S., Balestrieri, A., Smaldone, G., and Soricelli, A. (2025). GFAP, CHI3L1 and GCIPL Thickness as Baseline Predictors of Early Disability Progression in MS. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262411774"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"10923","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: Correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e200052","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"11772719211013352","DOI":"10.1177\/11772719211013352","article-title":"Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches","volume":"16","author":"Jafari","year":"2021","journal-title":"Biomark. Insights"},{"key":"ref_165","unstructured":"(2026, April 03). Sanofi Provides Update on Tolebrutinib Regulatory Submission in Non-Relapsing Secondary Progressive Multiple Sclerosis. Available online: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-12-24-06-00-00-3210238."},{"key":"ref_166","unstructured":"U.S. Food and Drug Administration (2025). Complete Response Letter for Tolebrutinib (NDA 219624)."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e70002","DOI":"10.1111\/liv.70002","article-title":"Drug-Induced Liver Injury Associated With Emerging Cancer Therapies","volume":"45","author":"Chodup","year":"2025","journal-title":"Liver Int."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.2023020974","article-title":"BTK inhibitors: Safety + efficacy = outcome","volume":"142","author":"Niemann","year":"2023","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/WCO.0000000000001275","article-title":"Pregnancy and reproductive health in women with multiple sclerosis: An update","volume":"37","author":"Houtchens","year":"2024","journal-title":"Curr. Opin. Neurol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e213907","DOI":"10.1212\/WNL.0000000000213907","article-title":"Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis","volume":"105","author":"Gavoille","year":"2025","journal-title":"Neurology"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Varyte, G., Zakareviciene, J., Ramasauskaite, D., Lauzikiene, D., and Arlauskiene, A. (2020). Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy\u2019s Impact on Disease Activity. Medicina, 56.","DOI":"10.3390\/medicina56020049"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e2531581","DOI":"10.1001\/jamanetworkopen.2025.31581","article-title":"Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability","volume":"8","author":"Shipley","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/1352458513519840","article-title":"Pregnancy, sex and hormonal factors in multiple sclerosis","volume":"20","author":"Miller","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e2989","DOI":"10.1212\/WNL.0000000000012084","article-title":"Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis","volume":"96","author":"Yeh","year":"2021","journal-title":"Neurology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/acn3.51893","article-title":"Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions","volume":"10","author":"Anderson","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Gklinos, P., and Dobson, R. (2023). Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050770"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-022-00421-0","article-title":"Multiple Sclerosis in Pregnancy: A Commentary on Disease Modification and Symptomatic Drug Therapies","volume":"12","author":"Iyer","year":"2023","journal-title":"Neurol. Ther."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1093\/ibd\/izae011","article-title":"Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn\u2019s Disease, and Relapsing Multiple Sclerosis","volume":"30","author":"Dubinsky","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00415-020-09762-y","article-title":"Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: Results from the European Interferon-beta Pregnancy Registry","volume":"267","author":"Hellwig","year":"2020","journal-title":"J. Neurol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40264-022-01168-1","article-title":"Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding","volume":"45","author":"Kaplan","year":"2022","journal-title":"Drug Saf."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1352458520929628","article-title":"Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study","volume":"27","author":"Pauliat","year":"2021","journal-title":"Mult. Scler."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"101137","DOI":"10.1016\/j.lanepe.2024.101137","article-title":"Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: A prospective cohort study from the German multiple sclerosis and pregnancy registry","volume":"48","author":"Bast","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ene.15559","article-title":"Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis","volume":"30","author":"Andersen","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: \u2019Association of British Neurologists\u2019 guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pr. Neurol."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Capone, F., Albanese, A., Quadri, G., Di Lazzaro, V., Falato, E., Cortese, A., De Giglio, L., and Ferraro, E. (2022). Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.851413"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1177\/13524585221083982","article-title":"Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis\u2014COBRA study","volume":"28","author":"Ciplea","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1212\/NXI.0000000000000757","article-title":"Safety of potential breast milk exposure to IFN-beta or glatiramer acetate: One-year infant outcomes","volume":"7","author":"Ciplea","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"101273","DOI":"10.1016\/j.blre.2025.101273","article-title":"BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies","volume":"71","author":"Liu","year":"2025","journal-title":"Blood Rev."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.2024026672","article-title":"Novel mechanisms of resistance in CLL: Variant BTK mutations in second-generation and noncovalent BTK inhibitors","volume":"145","author":"Tam","year":"2025","journal-title":"Blood"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/1078-0432.CCR-23-0409","article-title":"New Means and Challenges in the Targeting of BTK","volume":"30","author":"Nawaratne","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"233","DOI":"10.33549\/physiolres.935494","article-title":"Bruton\u2019s Tyrosine Kinase: A Potential Novel Target for Neurological Disorders","volume":"74","author":"Das","year":"2025","journal-title":"Physiol. Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e13332","DOI":"10.1111\/acel.13332","article-title":"Ibrutinib modulates Abeta\/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer\u2019s disease","volume":"20","author":"Lee","year":"2021","journal-title":"Aging Cell"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Bivona, G., Iemmolo, M., Agnello, L., Lo Sasso, B., Gambino, C.M., Giglio, R.V., Scazzone, C., Ghersi, G., and Ciaccio, M. (2023). Microglial Activation and Priming in Alzheimer\u2019s Disease: State of the Art and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010884"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., and Lan, J. (2023). Microglia in Alzheimer\u2019s disease: Pathogenesis, mechanisms, and therapeutic potentials. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1201982"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s43587-023-00424-y","article-title":"Human microglia show unique transcriptional changes in Alzheimer\u2019s disease","volume":"3","author":"Prater","year":"2023","journal-title":"Nat. Aging"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Cai, Y., Liu, J., Wang, B., Sun, M., and Yang, H. (2022). Microglia in the Neuroinflammatory Pathogenesis of Alzheimer\u2019s Disease and Related Therapeutic Targets. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.856376"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11481-019-09839-0","article-title":"Inhibition of Bruton\u2019s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer\u2019s Disease","volume":"14","author":"Keaney","year":"2019","journal-title":"J. Neuroimmune Pharmacol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/8\/1272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:36:51Z","timestamp":1776065811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/8\/1272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":198,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["molecules31081272"],"URL":"https:\/\/doi.org\/10.3390\/molecules31081272","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]}}}